TY - JOUR
T1 - Associations of serially measured PCSK9, LDLR and MPO with clinical outcomes in heart failure
AU - Bouwens, Elke
AU - Schuurman, Anne-Sophie
AU - Akkerhuis, Martijn
AU - Manintveld, Olivier
AU - Caliskan, Kadir
AU - van Ramshorst, J
AU - Germans, T
AU - Umans, VA
AU - Boersma, Eric
AU - Kardys, Isabella
N1 - Funding Information:
This work was supported by the Jaap Schouten Foundation and the Noordwest Academie, both nonprofit organizations.
Publisher Copyright:
© 2021 Future Medicine Ltd.
PY - 2021/3
Y1 - 2021/3
N2 - Aim: To investigate the temporal evolution of plasma proprotein convertase subtilisin/kexin type 9 (PCSK9), low-density lipoprotein receptor (LDLR) and myeloperoxidase (MPO) in relation to clinical outcome in chronic heart failure (CHF). Methodology & results: Trimonthly blood sampling was performed during a median follow-up of 2.2 (IQR 1.4-2.5) years in 263 CHF patients. Seventy patients reached the primary end point (PE) (cardiovascular death, heart transplantation, left ventricular assist device implantation or HF-hospitalization). MPO level was independently associated with the PE; the adjusted (for clinical factors) hazard ratio (aHR) per standard deviation difference in MPO was 1.71 (95% CI: 1.23-2.43) at any time during follow-up. PCSK9 level (HR: 1.45 [1.04-2.06]) and LDLR (HR: 0.66 [0.49-0.87]) were statistical significantly associated with the PE but only in unadjusted analyses. Slope of temporal MPO evolution (aHR: 1.34 [1.12-1.76] per 0.1 standard deviation/year difference in slope) and LDLR (aHR: 0.78 [0.61-0.90]) however, were associated with PE. Conclusion: Temporal patterns of MPO and LDLR are independently associated with clinical outcome in CHF, which illustrates the importance of assessing temporal evolutions.
AB - Aim: To investigate the temporal evolution of plasma proprotein convertase subtilisin/kexin type 9 (PCSK9), low-density lipoprotein receptor (LDLR) and myeloperoxidase (MPO) in relation to clinical outcome in chronic heart failure (CHF). Methodology & results: Trimonthly blood sampling was performed during a median follow-up of 2.2 (IQR 1.4-2.5) years in 263 CHF patients. Seventy patients reached the primary end point (PE) (cardiovascular death, heart transplantation, left ventricular assist device implantation or HF-hospitalization). MPO level was independently associated with the PE; the adjusted (for clinical factors) hazard ratio (aHR) per standard deviation difference in MPO was 1.71 (95% CI: 1.23-2.43) at any time during follow-up. PCSK9 level (HR: 1.45 [1.04-2.06]) and LDLR (HR: 0.66 [0.49-0.87]) were statistical significantly associated with the PE but only in unadjusted analyses. Slope of temporal MPO evolution (aHR: 1.34 [1.12-1.76] per 0.1 standard deviation/year difference in slope) and LDLR (aHR: 0.78 [0.61-0.90]) however, were associated with PE. Conclusion: Temporal patterns of MPO and LDLR are independently associated with clinical outcome in CHF, which illustrates the importance of assessing temporal evolutions.
UR - http://www.scopus.com/inward/record.url?scp=85101681279&partnerID=8YFLogxK
U2 - 10.2217/bmm-2020-0585
DO - 10.2217/bmm-2020-0585
M3 - Article
SN - 1752-0363
VL - 15
SP - 247
EP - 255
JO - Biomarkers in Medicine
JF - Biomarkers in Medicine
IS - 4
ER -